WRB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now. WRB’s near-term setup is capped by weakening analyst outlooks (multiple target cuts/downgrades tied to slowing premium growth and P&C cycle softening) and a bearish longer-term moving-average stack, while upside to nearby resistance looks limited versus downside to support. With no Intellectia buy signals and an impatient timeframe, I would avoid initiating a new position here and rate it a HOLD (not a buy).
Price ~68.62 (closed) is slightly above the pivot (67.53) but below/near key resistance at 69.40 (R1) and 70.56 (R2). Momentum is improving short-term (MACD histogram +0.144 and expanding; RSI-6 ~63 = mildly bullish/neutral), but the broader trend remains bearish with SMA_200 > SMA_20 > SMA_5 (longer-term down/weak structure). Risk/reward near-term: upside looks ~+1.1% to R1 versus downside ~-4.3% to S1 (65.66). Pattern-based odds also imply muted upside and slightly negative 1-month drift (-1.21%).
Intellectia Proprietary Trading Signals
Latest quarter: 2025/Q4. Revenue rose to ~$3.721B (+1.5% YoY), but profitability declined: net income ~$449.5M (-22.0% YoY) and EPS $1.13 (-21.5% YoY). Despite the YoY earnings drop, operating/underwriting quality looked strong (record underwriting income, combined ratio ex-cat 87.9%) and ROE was high (21.4%), suggesting the key concern is forward growth/pricing normalization rather than current underwriting discipline.
Recent trend is negative: a cluster of price-target cuts and several downgrades in January, largely tied to expectations for slower premium growth and valuation pressure as the P&C cycle softens. Notable calls: TD Cowen downgraded to Sell (PT $55); Barclays kept Underweight (PT $64); Evercore downgraded to Underperform (PT $69). Several neutrals cut targets (BofA to $66, Wells Fargo to $66, MS to $73, KBW to $74). The main bullish offset is Truist maintaining Buy (PT $80) but still cutting its target.
Wall Street pros: strong underwriting execution, high ROE, consistent capital return. Wall Street cons: decelerating premium growth, estimate-revision risk, and potential de-rating from a softer pricing cycle plus valuation concerns.
